Brent B.

Brent B. has extensive work experience in the field of biomarker development and molecular biology. Brent is currently serving as a Senior Director of clinical biomarker development at Loxo Oncology at Lilly since 2023. Prior to this, they worked at Eli Lilly and Company as an Associate Director, managing biomarker lead responsibilities from 2021 to 2023.

From 2007 to 2021, Brent held various positions at Merck, including Principal Scientist, Associate Principal Scientist, and Sr. Research Biologist. Brent contributed to translational molecular biomarker research and led biomarker groups in different projects.

Before joining Merck, Brent was a Scientist at Proteome Resources from 2005 to 2006, where they focused on the identification and development of new apoptosis reagents and protein purification.

Brent began their career as a Research Associate and later as a Post-doctoral Fellow at the University of Colorado from 2002 to 2005. In these roles, they conducted extensive research on cell lines and proteins, using various molecular biology and imaging techniques.

Overall, Brent B. has a strong background in biomarker development, molecular biology, and protein purification, with significant experience in leading and managing projects in the pharmaceutical industry.

Brent B. obtained a Ph.D. in Cancer Biology from the University of Arizona in 2002. Before that, they completed their B.A. in Biology/Chemistry at Point Loma Nazarene University from 1992 to 1996. Brent B.'s education started at Cibola High School from 1988 to 1992.